Corcept Therapeutics Incorporated (CORT)
After hours:
| Previous close | 23.52 |
| Open | 23.48 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 22.64 - 23.56 |
| 52-week range | 16.47 - 30.14 |
| Volume | |
| Avg. volume | 594,963 |
| Market cap | 2.477B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 22.56 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Corcept Therapeutics Provides Miricorilant Clinical Development Update
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic
- GlobeNewswire
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. ("Hikma") resolving patent litigation related to Korlym®, Corcept’s medication for the treatment
- GlobeNewswire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2022. Financial Results Revenue of $101.7 million, compared to $96.1 million in third quarter 2021Tightened 2022 revenue gui
